CorMedix Secures Major Patent Victory for MINOCIN® Against Generic Competitor
CRMD sits 38% above its 52-week low of $6.125.
Summary
CorMedix announced a significant patent litigation win, protecting its MINOCIN® for Injection product from generic competition and affirming the strength of its intellectual property.
Key Events · Legal and Risk Events · CRMD
-
Patent Validity Affirmed
The U.S. Court of Appeals for the Federal Circuit affirmed the validity of CorMedix's MINOCIN® for Injection patents.
-
Generic Infringement Confirmed
The court upheld the district court's judgment that Nexus Pharmaceuticals Inc.'s generic minocycline product infringed CorMedix's patents.
-
Permanent Injunction Issued
A permanent injunction was affirmed, barring Nexus from marketing its generic product prior to patent expiration, securing market exclusivity for MINOCIN®.
Analysis · CRMD · Life Sciences
The U.S. Court of Appeals for the Federal Circuit affirmed the validity of CorMedix's MINOCIN® for Injection patents and upheld a permanent injunction against Nexus Pharmaceuticals' generic product. This ruling protects a key revenue-generating product from generic competition, reinforcing the company's intellectual property and securing future sales. This follows recent positive news regarding Phase III trial results for REZZAYO and strong Q1 financials, adding to positive momentum.
At the time of this filing, CRMD was trading at $8.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $655.9M. The 52-week trading range was $6.13 to $17.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.